These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18368303

  • 61. [Treatment of orthostatic hypotension by noradrenaline supplement].
    Hayashi A.
    No To Shinkei; 1985 Jul; 37(7):665-9. PubMed ID: 3933534
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial.
    Kaufmann H, Vickery R, Wang W, Kanodia J, Shibao CA, Norcliffe-Kaufmann L, Haumann B, Biaggioni I.
    Clin Auton Res; 2021 Dec; 31(6):699-711. PubMed ID: 34657222
    [Abstract] [Full Text] [Related]

  • 64. Visceral orthostatic hypotension in patients with severe autonomic dysfunction.
    Terazaki H, Ando Y, Yamashita T, Obayashi K, Nakamura K, Nakamura M, Yoshimatsu S, Suga M, Uchino M, Ando M.
    J Auton Nerv Syst; 1998 Jan 19; 68(1-2):101-8. PubMed ID: 9531450
    [Abstract] [Full Text] [Related]

  • 65. Effect of L-threo-3, 4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury.
    Muneta S, Iwata T, Hiwada K, Murakami E, Sato Y, Imamura Y.
    Jpn Circ J; 1992 Mar 19; 56(3):243-7. PubMed ID: 1552652
    [Abstract] [Full Text] [Related]

  • 66. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
    Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ.
    J Clin Pharmacol; 2011 Jan 19; 51(1):66-74. PubMed ID: 20220040
    [Abstract] [Full Text] [Related]

  • 67. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP, Claassen D, Mehdirad A.
    Clin Auton Res; 2017 Jul 19; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract] [Full Text] [Related]

  • 68. Neurogenic orthostatic hypotension: new prospects in treatment. Introduction.
    Kaufmann H.
    Clin Auton Res; 2008 Mar 19; 18 Suppl 1():1. PubMed ID: 18368299
    [No Abstract] [Full Text] [Related]

  • 69. The cause of eyelid ptosis, orthostatic hypotension and exercise intolerance.
    Monnens L.
    Acta Paediatr; 2022 Jun 19; 111(6):1134-1136. PubMed ID: 35202494
    [Abstract] [Full Text] [Related]

  • 70. Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.
    Vernino S, Lew M, Kremens D.
    Clin Auton Res; 2017 Jul 19; 27(Suppl 1):35-37. PubMed ID: 28623420
    [No Abstract] [Full Text] [Related]

  • 71. Hemodynamic effects of L-threo-3,4-dihydroxyphenylserine (Droxidopa) in hypotensive individuals with spinal cord injury.
    Wecht JM, Rosado-Rivera D, Weir JP, Ivan A, Yen C, Bauman WA.
    Arch Phys Med Rehabil; 2013 Oct 19; 94(10):2006-12. PubMed ID: 23602882
    [Abstract] [Full Text] [Related]

  • 72. Effect of the somatostatin analogue SMS-201-995 on the adrenergic response to glucose ingestion in patients with postprandial hypotension.
    Hoeldtke RD, Dworkin GE, Gaspar SR, Israel BC, Boden G.
    Am J Med; 1989 Jun 19; 86(6 Pt 1):673-7. PubMed ID: 2658575
    [Abstract] [Full Text] [Related]

  • 73. Prospects for droxidopa in neurogenic orthostatic hypotension.
    Ross AJ, Stewart JM.
    Hypertension; 2015 Jan 19; 65(1):34-5. PubMed ID: 25350983
    [No Abstract] [Full Text] [Related]

  • 74. Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase.
    Mathias CJ, Bannister RB, Cortelli P, Heslop K, Polak JM, Raimbach S, Springall DR, Watson L.
    Q J Med; 1990 Jun 19; 75(278):617-33. PubMed ID: 2217667
    [Abstract] [Full Text] [Related]

  • 75. Inhibition of the norepinephrine transporter to treat neurogenic orthostatic hypotension: is this the end of the story?
    Lamotte G, Millar Vernetti P.
    Clin Auton Res; 2021 Dec 19; 31(6):645-647. PubMed ID: 34757507
    [No Abstract] [Full Text] [Related]

  • 76. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Claassen D, Lew M.
    Clin Auton Res; 2017 Jul 19; 27(Suppl 1):13-14. PubMed ID: 28631224
    [No Abstract] [Full Text] [Related]

  • 77. The Treatment of Primary Orthostatic Hypotension.
    Hale GM, Valdes J, Brenner M.
    Ann Pharmacother; 2017 May 19; 51(5):417-428. PubMed ID: 28092986
    [Abstract] [Full Text] [Related]

  • 78. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug.
    Goldstein DS.
    Cardiovasc Drug Rev; 2006 May 19; 24(3-4):189-203. PubMed ID: 17214596
    [Abstract] [Full Text] [Related]

  • 79. Norepinephrine Reuptake Inhibition, an Emergent Treatment for Neurogenic Orthostatic Hypotension.
    Mwesigwa N, Shibao CA.
    Hypertension; 2024 Jul 19; 81(7):1460-1466. PubMed ID: 38766862
    [Abstract] [Full Text] [Related]

  • 80. Droxidopa for Hypotension of Different Etiologies: Two Case Reports.
    Oommen J, Chen J, Wang S, Caraccio T, Hanna A.
    P T; 2019 Mar 19; 44(3):125-144. PubMed ID: 30828233
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.